Enlisting Immunotherapies in the Fight Against Infectious Diseases

Episode Summary

Executive Summary: Jeff Stein describes Sedera Therapeutics’ strategy for infectious disease as an oncology-inspired shift toward bispecific immunotherapies that combine a pathogen-targeting small molecule with a human antibody Fc effector domain. He argues current anti-infectives are outdated, resistance is worsening, and reimbursement challenges hinder antibiotic innovation, while Sedera aims to address bacterial, fungal, and viral infections and advance rezafungin into Phase III.

Main Topics: Innovation Gap in Infectious Disease (Priority: 5/5): Stein argues that antibacterial and broader anti-infective development has seen little fundamentally new innovation for decades, with most drugs still aimed at legacy targets. Cloudbreak Platform Mechanism (Priority: 5/5): Sedera’s Cloudbreak is a bispecific immunotherapy in which a modified small molecule targets the pathogen and a human antibody Fc fragment recruits the immune system for a localized response. Antibiotic Market and Reimbursement Challenges (Priority: 4/5): The conversation highlights the scientific need for new antibiotics alongside commercial barriers, especially poor reimbursement under DRG-based hospital payment models. Resistance and Broad Anti-Infective Potential (Priority: 4/5): Cloudbreak is positioned as a way to bypass or reduce resistance by modifying existing drugs and potentially applying the platform to bacteria, fungi, and viruses. Antifungal Need and Rezafungin Program (Priority: 5/5): Stein emphasizes the very limited antifungal arsenal and outlines Sedera’s Phase III plans for rezafungin in treatment and prophylaxis. Clinical Development Timeline and Outlook (Priority: 3/5): The interview closes with upcoming Phase III studies and expected readouts, underscoring near-term clinical milestones for the company.

Key Arguments: Infectious disease, especially antibacterial development, has lacked fundamentally new therapeutic approaches for decades. The rise of multidrug-resistant bacteria makes the need for innovation urgent while the pipeline of new drugs has shrunk. The GAIN Act helped by extending exclusivity and priority review, but it did not solve reimbursement economics, which discourage adoption of novel antibiotics. Cloudbreak adapts immuno-oncology logic to infection by pairing pathogen targeting with immune activation. Sedera’s platform uses a modified known drug as the targeting moiety and a human Fc fragment as the effector moiety. This design may improve pharmacokinetics, enable prophylactic as well as therapeutic use, and help address resistance. Gram-negative infections remain a major unmet need, and Sedera believes its approach fills a gap not covered by current pipeline drugs. Antifungal therapy is especially underserved because there are far fewer drug classes, with higher toxicity and drug-drug interaction issues. Rezafungin is positioned as a once-weekly echinocandin with pharmacokinetic properties intended to improve outcomes and facilitate earlier discharge from hospital. Sedera is expanding beyond antibacterials to antivirals, indicating the platform’s broader potential across infectious diseases.

Data Points: Bacterial infection targets in current development: Same set of targets used from the 1940s to recently - Stein says antibacterial R&D remains focused on legacy targets GAIN Act exclusivity extension: 5 additional years - Benefit for qualifying drugs under the 2012 law Fungal exposure per day: ~10,000 fungal cells inhaled every 24 hours - Used to explain how common exposure is and why immune failure matters Antibacterial drug classes: ~17 classes - Stein contrasts antibacterial diversity with antifungal scarcity Antifungal drug classes: 3 classes - Illustrates the limited antifungal treatment arsenal Echinocandin class age: ~17 years - Most recent antifungal class introduction Aspergillosis mortality: Up to 50% - Highlights severity of invasive fungal infections Candidemia / invasive candidiasis mortality: 30% to 70% - Supports urgency for better antifungals Rezafungin dosing: Once weekly - Key product attribute for Phase III development Rezafungin Phase III treatment study duration: About 2 years - Expected timeline for severe Candida infection trial Phase III prophylaxis population: Allogeneic bone marrow transplant patients - Planned prevention study for high-risk immunocompromised patients

Pivotal Quotes: "In infectious disease, that's clearly the case." — Jeff Stein: Answering whether a lack of innovation has been a problem in therapy development "What we're trying to do at Sidera is really inspired by what's happening in immuno-oncology, but at the same time it's combining that approach of having a small molecule drug directed against a target, but then engaging the human immune system to help amplify that effect." — Jeff Stein: Explaining the core concept behind Sedera’s anti-infective strategy "You know, there's a thing called DRG, Drug Related Group Reimbursement, where a hospital pharmacy gets a fixed payment. And it's in their best interest to keep that fixed payment to treat a patient." — Jeff Stein: Discussing why reimbursement can undermine commercialization of new antibiotics

Implications: Sedera is betting that immune-engaging anti-infectives can improve efficacy, durability, and prophylaxis while overcoming resistance. If successful, the platform could broaden treatment options in infection and reshape how novel anti-infectives are developed and used.